Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT04215978 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC)
Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG: BGB-A445
DRUG: tislelizumab

Sponsor

BeiGene